{"uri":"oral-versus-intravenous-methylprednisolone-for-tre-j5hcq36","version_id":"0","protocol_name":"Oral versus intravenous methylprednisolone for treatment of relapses in multiple sclerosis\uff1aa meta-analysis of randomized controlled trials.","protocol_name_html":"Oral versus intravenous methylprednisolone for treatment of relapses in multiple sclerosis\uff1aa meta-analysis of randomized controlled trials.","is_prepublished":"0","can_edit":"0","parent_id":null,"api_version":"1","is_new_mode":"0","last_modified":"1519884001","type_id":"1","link":"https:\/\/doi.org\/10.1371\/journal.pone.0188644","fork_id":"","public_fork_note":null,"number_of_steps":"8","has_versions":"0","first_published_date":"1506854057","publish_date":"2017-11-28 18:07:17","documents":null,"have_protocol_in_step":"0","is_protocol_in_step":"0","vendor_name":"Contributed by users","vendor_link":"https:\/\/www.protocols.io","vendor_logo":"\/img\/vendors\/1.png","mod_mins":"-45","mod_secs":"1","description":null,"is_bookmarked":"0","can_reassign":"1","before_start":null,"has_guidelines":"0","materials":[],"warning":null,"version_class":"8073","public":"1","is_owner":"1","is_original_owner":"1","created_on":"1506853093","protocol_affiliation":"first affiliated hospital of Shantou University Medical College","affiliation":null,"doi":"dx.doi.org\/10.17504\/protocols.io.j5hcq36","doi_status":"2","changed_fork_steps":null,"profile_url":"y2u25403y2","protocol_img":"https:\/\/www.protocols.io\/img\/default_protocol.png","profile_image":"\/img\/avatars\/018.png","full_name":"weiduan zhuang","created_by":"weiduan zhuang","private_link":"3D54B1D2C9CF3CDC60DD25E1571449D0","original_img":"1","username":"weiduan-zhuang","is_retracted":"0","retraction_reason":null,"plos_id":"10.1371\/journal.pone.0188644","manuscript_citation":"Liu S,  Liu X,  Chen S,  Xiao Y,  Zhuang W (2017) Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials. PLoS ONE  12(11): e0188644. doi: <a target=\"_blank\" href=\"https:\/\/dx.doi.org\/10.1371\/journal.pone.0188644\">10.1371\/journal.pone.0188644<\/a> ","journal_name":"PLOS One","is_donations_disabled":"0","is_donations_disabled_by_user":"9","item_record_id":267426,"fork_info":[],"compare_forks":[],"protocols":[],"groups":[],"number_of_shared_runs":[],"ownership_history":[],"keywords":"","transfer_to_user":[],"sub_transfer":false,"is_transfer_pending":false,"number_of_bookmarks":"0","collections":[],"tags":[],"archived":0,"sub_authors":[],"sub_protocols_number":0,"can_edit_shared":0,"shared_runs":[],"is_shared_run":0,"is_shared":1,"banner":null,"contact_badges":[{"badge_id":"2","badge_image":"\/img\/badges\/bronze.svg","badge_description":"Author!"},{"badge_id":"5","badge_image":"\/img\/badges\/earlyadopter.svg","badge_description":"Early adopter"}],"number_of_comments":0,"is_locked":0,"is_locked_by":false,"authors":"Shuo Liu","authors_list":[{"name":"Shuo Liu","affiliation":"first affiliated hospital of Shantou University Medical College","username":null,"profile_image":null}],"user":{"profile_image":"\/img\/avatars\/018.png","username":"weiduan-zhuang","full_name":"weiduan zhuang","created_by":"weiduan zhuang"},"access":{"can_view":"1","can_remove":"0","can_add":"0","can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":"0","can_move":"1","can_transfer":"1","can_download":"1","is_locked":"0"},"is_contact_suspended":0,"guidelines":null,"status_id":"1","is_research":null,"status_info":null,"steps":[{"id":"589186","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"B2B3843A0ED44AC194FD166537E02054","previous_guid":null,"previous_id":"0","last_modified":"1506853228","components":[{"component_id":"1008747","previous_id":0,"original_id":"0","guid":"5D863D96BE534E838DDE8255C07C84A3","previous_guid":null,"component_type_id":"6","data_id":"0","data":"Background","order_id":"0","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Background"},"is_project":0},{"component_id":"1008746","previous_id":"1008747","original_id":"0","guid":"3F5D6A21C49440F6A2E845714756B863","previous_guid":"5D863D96BE534E838DDE8255C07C84A3","component_type_id":"1","data_id":null,"data":"<p>Multiple sclerosis is an inflammatory demyelinating disease\uff0cwhich destroys myelin sheaths of neurons of central nervous system.\u00a0Glucocorticoid has been recommended as the first line treatment for relapses of MS. However, route of giving glucocorticoid has not be determined. A systemic review of five RCTs comparing oral and intravenous methylprednisolone for relapses of MS showed that there\u00a0is no significant differences in efficacy between oral and intravenous administration.\u00a0But the authors of this review indicated that there are some limitations of this study such as\u00a0methodological weaknesses, insufficient statistical power, small trial number and small number of participants. They called for more large scale trials to be done. And in 2015, a large, adequately powered, randomized controlled trial comparing oral versus intravenous methylprednisolone was reported.<\/p>","order_id":"1","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>Multiple sclerosis is an inflammatory demyelinating disease\uff0cwhich destroys myelin sheaths of neurons of central nervous system.\u00a0Glucocorticoid has been recommended as the first line treatment for relapses of MS. However, route of giving glucocorticoid has not be determined. A systemic review of five RCTs comparing oral and intravenous methylprednisolone for relapses of MS showed that there\u00a0is no significant differences in efficacy between oral and intravenous administration.\u00a0But the authors of this review indicated that there are some limitations of this study such as\u00a0methodological weaknesses, insufficient statistical power, small trial number and small number of participants. They called for more large scale trials to be done. And in 2015, a large, adequately powered, randomized controlled trial comparing oral versus intravenous methylprednisolone was reported.<\/p>"},"is_project":0}]},{"id":"589187","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"4F86E8081CDB43D783D974FE5EBD2D22","previous_guid":"B2B3843A0ED44AC194FD166537E02054","previous_id":"589186","last_modified":"1506853292","components":[{"component_id":"1008749","previous_id":0,"original_id":"0","guid":"E6C575888E7345A894C707450611732A","previous_guid":null,"component_type_id":"6","data_id":"0","data":"Why it is important to do this review","order_id":"0","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Why it is important to do this review"},"is_project":0},{"component_id":"1008748","previous_id":"1008749","original_id":"0","guid":"7A5C060DEAC34A8C87A68E80B4651C01","previous_guid":"E6C575888E7345A894C707450611732A","component_type_id":"1","data_id":null,"data":"<p>Intravenous glucocorticoid\u00a0will increase cost, need hospitalization and influence daily life while oral glucocorticoid is cheaper, less invasive and more convenient.\u00a0So we do this meta-analysis to find out whether oral glucocorticoid\u00a0can be an effective alternative to intravenous steroids for MS relapse.\u00a0<\/p>","order_id":"1","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>Intravenous glucocorticoid\u00a0will increase cost, need hospitalization and influence daily life while oral glucocorticoid is cheaper, less invasive and more convenient.\u00a0So we do this meta-analysis to find out whether oral glucocorticoid\u00a0can be an effective alternative to intravenous steroids for MS relapse.\u00a0<\/p>"},"is_project":0}]},{"id":"589188","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"2B16A7C61BB44EC78E0F075BA49633CA","previous_guid":"4F86E8081CDB43D783D974FE5EBD2D22","previous_id":"589187","last_modified":"1506853575","components":[{"component_id":"1008751","previous_id":0,"original_id":"0","guid":"8B9BBE4504184F5E95C2FD0FE8EF8A78","previous_guid":null,"component_type_id":"6","data_id":"0","data":"Objectives","order_id":"0","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Objectives"},"is_project":0},{"component_id":"1008750","previous_id":"1008751","original_id":"0","guid":"90B6DD7FB0AC4FBAA59F208B031DF50E","previous_guid":"8B9BBE4504184F5E95C2FD0FE8EF8A78","component_type_id":"1","data_id":null,"data":"<p>To compare efficacy and safety between oral and intravenous methylprednisolone.<\/p>\n<p>.<\/p>","order_id":"1","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>To compare efficacy and safety between oral and intravenous methylprednisolone.<\/p>\n<p>.<\/p>"},"is_project":0}]},{"id":"589189","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"F8F56A3C3891426C946519469DE17624","previous_guid":"2B16A7C61BB44EC78E0F075BA49633CA","previous_id":"589188","last_modified":"1506853318","components":[{"component_id":"1008753","previous_id":0,"original_id":"0","guid":"91D6B9DCF06B437C9ECF4A1EB6697ABA","previous_guid":null,"component_type_id":"6","data_id":"0","data":"Design","order_id":"0","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Design"},"is_project":0},{"component_id":"1008752","previous_id":"1008753","original_id":"0","guid":"4AC7B091A891449BB4413DE9B19BB444","previous_guid":"91D6B9DCF06B437C9ECF4A1EB6697ABA","component_type_id":"1","data_id":null,"data":"<p>Traditional meta analysis.<\/p>","order_id":"1","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>Traditional meta analysis.<\/p>"},"is_project":0}]},{"id":"589190","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"A8435E3934514E9C9328A2E27081F264","previous_guid":"F8F56A3C3891426C946519469DE17624","previous_id":"589189","last_modified":"1506853342","components":[{"component_id":"1008755","previous_id":0,"original_id":"0","guid":"9C224155288449009EE40D2A68C1667D","previous_guid":null,"component_type_id":"6","data_id":"0","data":"Data Source","order_id":"0","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Data Source"},"is_project":0},{"component_id":"1008754","previous_id":"1008755","original_id":"0","guid":"0456706133964AADA282B89F7F96913B","previous_guid":"9C224155288449009EE40D2A68C1667D","component_type_id":"1","data_id":null,"data":"<p>PubMed, EMBASE,\u00a0Cochrane Library, MEDLINE and China\u00a0Biology\u00a0Medicine.<\/p>","order_id":"1","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>PubMed, EMBASE,\u00a0Cochrane Library, MEDLINE and China\u00a0Biology\u00a0Medicine.<\/p>"},"is_project":0}]},{"id":"589191","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"309CB8A62A8D4940AA01C21D57ACD154","previous_guid":"A8435E3934514E9C9328A2E27081F264","previous_id":"589190","last_modified":"1506853635","components":[{"component_id":"1008757","previous_id":0,"original_id":"0","guid":"D0C5CDDF7D054FBEACB557D7AF18ED4B","previous_guid":null,"component_type_id":"6","data_id":"0","data":"Methods","order_id":"0","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Methods"},"is_project":0},{"component_id":"1008756","previous_id":"1008757","original_id":"0","guid":"57B9B848F9E940AA8D11DF3B094DA87A","previous_guid":"D0C5CDDF7D054FBEACB557D7AF18ED4B","component_type_id":"1","data_id":null,"data":"<p>Randomized controlled trials of oral glucocorticoid\u00a0compared with intravenous\u00a0methylprednisolone\u00a0for\u00a0multiple sclerosis. Two reviewers\u00a0independently checked the quality of RCTs. Another two investigators\u00a0independently extracted data. The primary efficacy outcomes (proportion of patients experiencing improvement in oral\u00a0methylprednisolone vs intravenous\u00a0methylprednisolone at four weeks.) and adverse events\u00a0were summarized for meta analysis.\u00a0Stata software was used for traditional meta analysis.<\/p>","order_id":"1","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>Randomized controlled trials of oral glucocorticoid\u00a0compared with intravenous\u00a0methylprednisolone\u00a0for\u00a0multiple sclerosis. Two reviewers\u00a0independently checked the quality of RCTs. Another two investigators\u00a0independently extracted data. The primary efficacy outcomes (proportion of patients experiencing improvement in oral\u00a0methylprednisolone vs intravenous\u00a0methylprednisolone at four weeks.) and adverse events\u00a0were summarized for meta analysis.\u00a0Stata software was used for traditional meta analysis.<\/p>"},"is_project":0}]},{"id":"589192","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"128A61EA48E64FF9BF0A55825D9C0BE8","previous_guid":"309CB8A62A8D4940AA01C21D57ACD154","previous_id":"589191","last_modified":"1506853413","components":[{"component_id":"1008759","previous_id":0,"original_id":"0","guid":"021A92ABDD6D4F77AF6E232A521411B9","previous_guid":null,"component_type_id":"6","data_id":"0","data":"Results","order_id":"0","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Results"},"is_project":0},{"component_id":"1008758","previous_id":"1008759","original_id":"0","guid":"D5A8C0E8AE3747D089407023ED7F3831","previous_guid":"021A92ABDD6D4F77AF6E232A521411B9","component_type_id":"1","data_id":null,"data":"<p>A total of 5 trials were identified, including 369 patients. The results of our meta-analysis revealed that no significant difference existed in relapse improvement at day 28 between oMP and ivMP\u00a0(risk ratio (RR) 0.96, 95% confidence interval (95% CI) 0.84 to 1.10). No evidence of heterogeneity appeared among the trials (P=0.45, I<sup>2<\/sup>\u00a0=0%). Both treatments were equally safe and well tolerated except\u00a0that insomnia was more likely to occur in oMP group than ivMP group.<\/p>","order_id":"1","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>A total of 5 trials were identified, including 369 patients. The results of our meta-analysis revealed that no significant difference existed in relapse improvement at day 28 between oMP and ivMP\u00a0(risk ratio (RR) 0.96, 95% confidence interval (95% CI) 0.84 to 1.10). No evidence of heterogeneity appeared among the trials (P=0.45, I<sup>2<\/sup>\u00a0=0%). Both treatments were equally safe and well tolerated except\u00a0that insomnia was more likely to occur in oMP group than ivMP group.<\/p>"},"is_project":0}]},{"id":"589193","is_changed":"0","original_id":"0","is_skipped":"0","is_checked":"0","guid":"3B8B451624AD49F4A421DE03E7C49C99","previous_guid":"128A61EA48E64FF9BF0A55825D9C0BE8","previous_id":"589192","last_modified":"1506853430","components":[{"component_id":"1008761","previous_id":0,"original_id":"0","guid":"2A7D3901E7144163A8394337BBE7A999","previous_guid":null,"component_type_id":"6","data_id":"0","data":"Conclusion","order_id":"0","name":"Section","data_by_id":"0","type_id":"6","source_data":{"section":"Conclusion"},"is_project":0},{"component_id":"1008760","previous_id":"1008761","original_id":"0","guid":"2F4387A005EC4FC8ADE28EDC01816C8A","previous_guid":"2A7D3901E7144163A8394337BBE7A999","component_type_id":"1","data_id":null,"data":"<p>Our meta-analysis furnishes strong evidence that oMP is noninferior to ivMP in increasing proportion of patients experiencing improvement at day 28. And both routes of administration are equally well tolerated and safe. This finding suggests that we may replace ivMP with oMP to treat MS relapses.<\/p>","order_id":"1","name":"Description","data_by_id":"0","type_id":"1","source_data":{"description":"<p>Our meta-analysis furnishes strong evidence that oMP is noninferior to ivMP in increasing proportion of patients experiencing improvement at day 28. And both routes of administration are equally well tolerated and safe. This finding suggests that we may replace ivMP with oMP to treat MS relapses.<\/p>"},"is_project":0}]}]}